Clinical Trial Update: Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 12.5 mcg/h fentanyl transdermal patch titration with oral morphine for opioid-naïve patients experiencing moderate cancer pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Pain
• Opioid-naïve Cancer Pain

Drugs mentioned

• Morphine (oral) (Morphine)
• fentanyl transdermal patch 12.5 mcg/h (fentanyl)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive | Phase 3 | Status: UNKNOWN